{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:43:10Z","timestamp":1792816990965,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09032-0","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T06:12:53Z","timestamp":1756793573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Study protocol: COPD\u2013eosinophil-guided reduction of inhaled corticosteroids (COPERNICOS)"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-4983","authenticated-orcid":false,"given":"Christian","family":"R\u00f8nn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bonnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane Achir","family":"Alispahic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Lindhardt","family":"T\u00f8nnesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Lyngby","family":"Kj\u00e6rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Moberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Suppli","family":"Ulrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitta Barrella","family":"Harboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Browatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-9177","authenticated-orcid":false,"given":"Torben Tranborg","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian N","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"Bodtger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-6963","authenticated-orcid":false,"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Lock","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Utech","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-8671","authenticated-orcid":false,"given":"Charlotte","family":"Hyldgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeesh","family":"Sivapalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrik St\u00e6hr","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"9032_CR1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.05.020415","volume":"5","author":"D Adeloye","year":"2015","unstructured":"Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5: 020415.","journal-title":"J Glob Health"},{"issue":"10082","key":"9032_CR2","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(17)31222-9","volume":"389","author":"KF Rabe","year":"2017","unstructured":"Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931\u201340.","journal-title":"Lancet"},{"issue":"1","key":"9032_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1183\/13993003.01391-2014","volume":"47","author":"S Hartl","year":"2016","unstructured":"Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, Castro-Acosta A, Studnicka M, Kaiser B, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016;47(1):113\u201321.","journal-title":"Eur Respir J"},{"issue":"5","key":"9032_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","volume":"195","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557\u201382.","journal-title":"Am J Respir Crit Care Med"},{"key":"9032_CR5","doi-asserted-by":"crossref","unstructured":"Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD Science Committee Report 2019. Eur Respir J. 2019;53(5):1900164.","DOI":"10.1183\/13993003.00164-2019"},{"issue":"1","key":"9032_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1513\/AnnalsATS.201409-413OC","volume":"12","author":"C Crim","year":"2015","unstructured":"Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12(1):27\u201334.","journal-title":"Ann Am Thorac Soc"},{"key":"9032_CR7","doi-asserted-by":"crossref","unstructured":"Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018;52(6):1801219.","DOI":"10.1183\/13993003.01219-2018"},{"issue":"1","key":"9032_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41533-019-0150-x","volume":"29","author":"DB Price","year":"2019","unstructured":"Price DB, Voorham J, Brusselle G, Clemens A, Kostikas K, Stephens JW, et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim Care Respir Med. 2019;29(1):38.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"11","key":"9032_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.amjmed.2010.06.019","volume":"123","author":"S Suissa","year":"2010","unstructured":"Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001\u20136.","journal-title":"Am J Med"},{"key":"9032_CR10","doi-asserted-by":"publisher","first-page":"147997311986794","DOI":"10.1177\/1479973119867949","volume":"16","author":"O Savran","year":"2019","unstructured":"Savran O, Godtfredsen N, S\u00f8rensen T, Jensen C, Ulrik CS. COPD patients prescribed inhaled corticosteroid in general practice: Based on disease characteristics according to guidelines? Chron Respir Dis. 2019;16:1479973119867949.","journal-title":"Chron Respir Dis"},{"issue":"3","key":"9032_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/thx.2004.032516","volume":"60","author":"CE Brightling","year":"2005","unstructured":"Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193\u20138.","journal-title":"Thorax"},{"issue":"2","key":"9032_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","volume":"6","author":"M Bafadhel","year":"2018","unstructured":"Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117\u201326.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"9032_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","volume":"138","author":"PJ Barnes","year":"2016","unstructured":"Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16\u201327.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9032_CR14","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037-47e10.","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"9032_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","volume":"4","author":"H Watz","year":"2016","unstructured":"Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390\u20138.","journal-title":"Lancet Respir Med"},{"issue":"14","key":"9032_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"9032_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(19)30176-6","volume":"7","author":"P Sivapalan","year":"2019","unstructured":"Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699\u2013709.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"9032_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","volume":"2","author":"S Uzun","year":"2014","unstructured":"Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van\u2019t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361\u20138.","journal-title":"Lancet Respir Med."},{"issue":"8","key":"9032_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMoa1104623","volume":"365","author":"RK Albert","year":"2011","unstructured":"Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689\u201398.","journal-title":"N Engl J Med"},{"issue":"1","key":"9032_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/thoraxjnl-2016-208599","volume":"72","author":"LN Segal","year":"2017","unstructured":"Segal LN, Clemente JC, Wu BG, Wikoff WR, Gao Z, Li Y, et al. Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung. Thorax. 2017;72(1):13\u201322.","journal-title":"Thorax"},{"issue":"11","key":"9032_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30348-0","volume":"7","author":"P Sivapalan","year":"2019","unstructured":"Sivapalan P, Jensen JU. Non-eosinophilic severe exacerbations of COPD: what about antibiotics? \u2013 Authors\u2019 reply. Lancet Respir Med. 2019;7(11): e34.","journal-title":"Lancet Respir Med"},{"key":"9032_CR22","doi-asserted-by":"crossref","unstructured":"Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4).","DOI":"10.1183\/13993003.00451-2017"},{"key":"9032_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hr\u00f3bjartsson A, Schulz KF, Parulekar WR, Krle\u017ea-Jeri\u0107 K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346: e7586.","journal-title":"BMJ"},{"issue":"23","key":"9032_CR24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222\u201334.","journal-title":"N Engl J Med"},{"issue":"1","key":"9032_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000407","volume":"6","author":"P Sivapalan","year":"2019","unstructured":"Sivapalan P, Ingebrigtsen TS, Rasmussen DB, Sorensen R, Rasmussen CM, Jensen CB, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019;6(1): e000407.","journal-title":"BMJ Open Respir Res"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09032-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09032-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:13:47Z","timestamp":1757477627000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09032-0"}},"subtitle":["A randomized, double-blinded, multicenter, four-arm intervention clinical trial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic low dose Azithromycin therapy in patients with severe or very severe chronic obstructive pulmonary disease (COPD)"],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9032"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09032-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4006117\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research project will be carried out in accordance with the Helsinki Declaration, the Danish Data Protection Act, the Danish Health Act, and the General Data Protection Regulation (EU) 2016\/679 (GDPR).The study is approved through the CTIS and will be conducted in compliance with the Clinical Trials Regulation (EU) No 536\/2014 (CTR) and with the principles of good clinical practice, as this statement is a requirement under the CTR.The study will be registered in the US Clinical Trials database (\n                      \n                      ), which is based on guidelines defined by the Food and Drug Administration.Since study participants will not be exposed to irresponsible risks and can greatly benefit from the study\u2019s results and participation in the study, we believe that the study is scientifically and ethically sound.Participation in the trial is voluntary, and participants will not receive any form of financial compensation for participation. Participants are protected under the Personal Data Processing Act, and the study is reported to the Regional Science Ethics Committee (VEK), the Danish Medicines Agency (L\u00e6gemiddelstyrelsen), and the Danish Data Protection Agency (Videnscenter for Dataanmeldelser).The trial is covered by the patient compensation scheme. Participants can apply for compensation in accordance with Statutory Order No. 1113 of 7 November 2011 on the right of appeal and compensation in the healthcare system if participants experience unexpected damage during the trial or at inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Outside the submitted work: CSU has received grants from Sanofi, Boehringer Ingelheim, AstraZeneca, and Novartis; speaker fees from Orion Pharma, AstraZeneca, and TEVA; and consulting fees from Chiesi, Orion Pharma, AstraZeneca, GSK, and TEVA and has been on advisory boards for Novartis, Sanofi, GlaxoSmith Kline, Chiesi, AstraZeneca, and Boehringer Ingelheim. EB reports a grant from Boehringer Ingelheim; fees for presentations from BI and Chiesi; support for travel from Boehringer Ingelheim and Roche; has participated on Data Safety Monitoring Boards or advisory boards for AbbVie and Boehringer Ingelheim. JV has received consulting fees from AstraZeneca for serving on a trial steering committee, and has received payment or honoraria for presenting at meetings from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}